Pratap Paruchuru

2 months ago | onlinelibrary.wiley.com | Michele Senni |Victor Shi |Michael Bohm |Pratap Paruchuru

Sacubitril/valsartan, an angiotensin receptor–neprilysin inhibitor (ARNI), is recommended by the 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America guideline for heart failure (HF) in patients with HF with reduced ejection faction, New York Heart Association class II−III, and by the 2021 European Society of Cardiology (ESC) guidelines to replace angiotensin-converting enzyme inhibitors (ACEIs) for reducing HF hospitalizations and death risk.1, 2...